LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Nov 18, 2019
Tyrosine kinase inhibitors for the treatment of pemphigus
Read More
BioCentury
|
Oct 11, 2019
Targets & Mechanisms
CAR Ts can move well beyond cancer, but will need to go allogeneic first
CAR Ts could move into autoimmunity, infections and more, if researchers can solve the allogeneic question.
Read More
BioCentury
|
Jan 24, 2019
Emerging Company Profile
Cabaletta’s CAAR Ts for autoimmunity
How Cabaletta is treating B cell-mediated autoimmunity without wiping out all B cells
Read More
BioCentury
|
Jan 4, 2019
Financial News
Venture roundup: Cabaletta, Thousand Oaks, Sojournix
Read More
BioCentury
|
Jan 3, 2019
Financial News
Venture roundup: Cabaletta, Thousand Oaks, Sojournix
Read More
BioCentury
|
Nov 9, 2018
Financial News
Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A
Read More
BioCentury
|
Nov 8, 2018
Financial News
Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A
Read More
BioCentury
|
Jul 21, 2016
Distillery Therapeutics
Therapeutics: Desmoglein 3 (DSG3)
Read More
BioCentury
|
Jul 21, 2016
Tools & Techniques
A new route for CARs
Adapting CAR T technology to treat autoimmune diseases
Read More
BioCentury
|
Nov 13, 2006
Company News
Peptimmune, Orphan Europe deal
Read More
Items per page:
10
1 - 10 of 12